Evidence map›Paper›PMID 42720813›Full record

ArticleHuman genetics2026

Optical genome mapping improves structural variant detection and characterization in syndromic and neurogenetic disorders.

Rosa Catalina Lederbogen, Sabine Hoffjan, Cornelia Köhler, Charlotte Thiels, Ulrike Angelika Mau-Holzmann, Sylke Singer, Sabrina Schreiber, Anne Purczeld, Rebecca Buchert, Maria Viktorovna Yusenko and 2 more

Abstract read
In one paragraph

Article in Human genetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Rosa Catalina LederbogenDepartment of Human Genetics, Ruhr-University, 44801, Bochum, Germany.ORCID http://orcid.org/0009-0002-4033-0242
Sabine HoffjanDepartment of Human Genetics, Ruhr-University, 44801, Bochum, Germany.ORCID http://orcid.org/0009-0009-6280-1931
Cornelia KöhlerCenter for Rare Diseases Ruhr (CeSER), 44791, Bochum, Germany.
Charlotte ThielsCenter for Rare Diseases Ruhr (CeSER), 44791, Bochum, Germany.ORCID http://orcid.org/0000-0002-8582-7458
Ulrike Angelika Mau-HolzmannInstitute of Medical Genetics and Applied Genomics, University Tübingen, 72076, Tübingen, Germany.ORCID http://orcid.org/0000-0002-4125-4643
Sylke SingerInstitute of Medical Genetics and Applied Genomics, University Tübingen, 72076, Tübingen, Germany.
Sabrina SchreiberMVZ Dr. Eberhard & Partner, 44137, Dortmund, Germany.ORCID http://orcid.org/0000-0003-3823-3224
Anne PurczeldLADR Medizinisches Versorgungszentrum Recklinghausen eGbR, 45659, Recklinghausen, Germany.
Rebecca BuchertInstitute of Medical Genetics and Applied Genomics, University Tübingen, 72076, Tübingen, Germany.ORCID http://orcid.org/0000-0001-7576-3326
Maria Viktorovna YusenkoDepartment of Human Genetics, Ruhr-University, 44801, Bochum, Germany.ORCID http://orcid.org/0000-0002-9014-6542
Hoa Huu Phuc NguyenDepartment of Human Genetics, Ruhr-University, 44801, Bochum, Germany.ORCID http://orcid.org/0000-0001-6139-788X
Wanda Maria GerdingDepartment of Human Genetics, Ruhr-University, 44801, Bochum, Germany. wanda.gerding@rub.de.ORCID http://orcid.org/0000-0002-3858-9872

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Optical Genome Mapping (OGM) offers superior resolution compared to standard diagnostic methods such as karyotyping and FISH, enabling the detection of nearly all types of chromosomal aberrations with non-centromeric breakpoints. This study evaluated OGM's potential to enhance the genetic findings in unsolved cases of neurogenetic and syndromic disease requiring further investigation after standard genetic testing. In 10 patients with various neurogenetic diagnoses, OGM confirmed all structural findings previously detected by karyotyping, chromosomal microarray (CMA), and/or NGS. Moreover, OGM provided additional structural insights in five cases, such as identifying a novel candidate gene in a patient with a balanced translocation, redefining of breakpoint regions in familial translocations, characterization of complex rearrangements, and revising of initial diagnostic interpretations. Most importantly, we present OGM results for three individuals with ring chromosomes 18, 20, and 22, highlighting the need to adjust filter settings and to incorporate the rare variant pipeline for accurate detection. Based on our experiences, we propose a strategic approach for identifying ring chromosomes using OGM. On the other hand, OGM did not identify causative variants in three unsolved cases with strong clinical suspicion of hereditary neuropathy. In summary, while OGM did not yield new insights for hereditary neuropathy, it provided additional or refined information in 6 out of 10 cases with other syndromic diseases. These findings underscore the value of OGM in increasing the diagnostic yield and precision of genetic testing.

Indexed as

Chromosome MappingGenome, HumanNervous System DiseasesChromosome AberrationsFemaleHumansIn Situ Hybridization, FluorescenceKaryotypingMaleTranslocation, Genetic

Identifiers

PMID42720813
PMCPMC13562348

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.